Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome

Rituximab is one of the first-line therapies for patients with membranous nephropathy (MN) at high risk of progression towards kidney failure. We investigated whether the response to Rituximab was affected by sex and anti-PLA(2)R antibody levels in 204 consecutive patients (148 males and 56 females)...

Descripción completa

Detalles Bibliográficos
Autores principales: Perna, Annalisa, Ruggiero, Barbara, Podestà, Manuel Alfredo, Perico, Luca, Orisio, Silvia, Debiec, Hanna, Remuzzi, Giuseppe, Ruggenenti, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479107/
https://www.ncbi.nlm.nih.gov/pubmed/36120314
http://dx.doi.org/10.3389/fphar.2022.958136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479107/
https://www.ncbi.nlm.nih.gov/pubmed/36120314
http://dx.doi.org/10.3389/fphar.2022.958136

Ejemplares similares